| 1. |
- Beal, Jacob, et al.
(författare)
-
Robust estimation of bacterial cell count from optical density
- 2020
-
Ingår i: Communications Biology. - : Springer Science and Business Media LLC. - 2399-3642. ; 3:1
-
Tidskriftsartikel (refereegranskat)abstract
- Optical density (OD) is widely used to estimate the density of cells in liquid culture, but cannot be compared between instruments without a standardized calibration protocol and is challenging to relate to actual cell count. We address this with an interlaboratory study comparing three simple, low-cost, and highly accessible OD calibration protocols across 244 laboratories, applied to eight strains of constitutive GFP-expressing E. coli. Based on our results, we recommend calibrating OD to estimated cell count using serial dilution of silica microspheres, which produces highly precise calibration (95.5% of residuals <1.2-fold), is easily assessed for quality control, also assesses instrument effective linear range, and can be combined with fluorescence calibration to obtain units of Molecules of Equivalent Fluorescein (MEFL) per cell, allowing direct comparison and data fusion with flow cytometry measurements: in our study, fluorescence per cell measurements showed only a 1.07-fold mean difference between plate reader and flow cytometry data.
|
|
| 2. |
|
|
| 3. |
- Rizik, David G., et al.
(författare)
-
Long-term Outcomes of Transcatheter Aortic Valve Replacement With the Lotus Valve vs CoreValve/EvolutR : A Secondary Analysis of the REPRISE III Randomized Clinical Trial
- 2022
-
Ingår i: JAMA Network Open. - : American Medical Association (AMA). - 2574-3805. ; 5:10, s. 1-11
-
Tidskriftsartikel (refereegranskat)abstract
- Importance: Long-term follow-up after transcatheter aortic valve replacement (TAVR) is of interest given that longitudinal data on mortality and durability of transcatheter heart valves are limited. The REPRISE III (Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System-Randomized Clinical Evaluation) randomized clinical trial compared the mechanically expanded Lotus valve with the self-expanding CoreValve/EvolutR TAVR platforms. Objective: To describe the final 5-year outcomes of the REPRISE III trial. Design, Setting, and Participants: This prespecified secondary analysis assessed the final 5-year clinical, functional, and echocardiographic outcomes of 912 patients from the REPRISE III trial, which was conducted at 55 centers in North America, Europe, and Australia between September 22, 2014, and December 24, 2015. Patients had high risk for aortic stenosis or severe or symptomatic aortic stenosis. Data were analyzed from September 22, 2014, to May 21, 2021. Intervention: Lotus valve or CoreValve/EvolutR TAVR platforms. Main Outcomes and Measures: Valve Academic Research Consortium-2 end points, hemodynamic measures, functional status, and health status were examined through the 5-year follow-up. Results: A total of 912 patients (mean [SD] age, 82.8 [7.3] years; 463 women [50.8%]) were randomized to either the Lotus valve group (n = 607) or CoreValve/EvolutR group (n = 305), with a baseline Society of Thoracic Surgeons risk score of 6.8%. Clinical follow-up data from the REPRISE III trial were available for 581 patients (95.7%) in the Lotus valve group and 285 patients (93.4%) in the CoreValve/EvolutR group. At 5 years, the cumulative event rate for all-cause mortality was 50.9% in the Lotus valve group vs 52.8% in the CoreValve/EvolutR group (P = .59). Disabling stroke was less frequent with the Lotus valve vs CoreValve/EvolutR (cumulative event rates, 8.3% vs 12.2%; P = .04), whereas the cumulative event rates for overall stroke were similar in both groups (14.1% vs 15.3%; P = .38). Insertion of a new permanent pacemaker (38.9% vs 27.3%; P < .001) and detection of prosthetic aortic valve thrombosis (5.8% vs 1.8%; P = .007) were more common in the Lotus valve group than in the CoreValve/EvolutR group. A smaller proportion of patients who received the Lotus valve experienced valve malpositioning (0% vs 2.6%; P < .001) and required the use of a second valve (1.0% vs 3.8%; P < .001) during the procedure compared with those who received the CoreValve/EvolutR. Compared with the Lotus valve group, the CoreValve/EvolutR group had a significantly lower mean (SD) aortic gradient (7.8 [4.2] mm Hg vs 12.6 [6.7] mm Hg; P < .001) and larger valve areas (1.57 [0.56] cm2 vs 1.42 [0.42] cm2; P = .10). After 5 years, the proportion of patients with moderate or greater paravalvular leak was not significantly higher with the CoreValve/EvolutR than with the Lotus valve (1.9% vs 0%; P = .31); however, the proportion of patients with mild paravalvular leak was higher in the CoreValve/EvolutR group compared with the Lotus valve group (23.1% vs 7.8%; P = .006). Long-term, similar improvements in New York Heart Association class and Kansas City Cardiomyopathy Questionnaire score were observed in both groups. Conclusions and Relevance: The REPRISE III trial found that, at 5 years, the clinical outcomes of the Lotus valve were comparable to those of the CoreValve/EvolutR and that the Lotus valve was safe and effective. Trial Registration: ClinicalTrials.gov Identifier: NCT02202434.
|
|
| 4. |
- Viola, N., et al.
(författare)
-
H2020 STRATOFLY PROJECT : FROM EUROPE TO AUSTRALIA IN LESS THAN 3 HOURS
- 2021
-
Ingår i: 32nd Congress of the International Council of the Aeronautical Sciences, ICAS 2021. - 9783932182914
-
Konferensbidrag (refereegranskat)abstract
- As eluded in previous studies, with special reference to those carried out in the European framework, some innovative high-speed aircraft configurations have now the potential to assure an economically viable high-speed aircraft fleet. They make use of unexploited flight routes in the stratosphere, offering a solution to the presently congested flight paths while ensuring a minimum environmental impact in terms of emitted noise and green-house gases, particularly during stratospheric cruise. However, only a dedicated multi-disciplinary integrated design approach could realize this, by considering airframe architectures embedding the propulsion systems as well as meticulously integrating crucial subsystems. In this context, starting from an in-depth investigation of the current status of the activities, the STRATOFLY project has been funded by the European Commission, under the framework of Horizon 2020 plan, with the aim of assessing the potential of this type of high-speed transport vehicle to reach Technology Readiness Level (TRL) 6 by 2035, with respect to key technological, societal and economical aspects. This paper aims at summarizing the main results achieved so far to solve the main issues related to thermal and structural integrity, low-emissions combined propulsion cycles, subsystems design and integration, including smart energy management, environmental aspects impacting climate change, noise emissions and social acceptance, and economic viability accounting for safety and human factors.
|
|
| 5. |
- Viola, Nicole, et al.
(författare)
-
Stratofly mr3 – how to reduce the environmental impact of high-speed transportation
- 2021
-
Ingår i: AIAA Scitech 2021 Forum. - 9781624106095 ; , s. 1-21
-
Konferensbidrag (refereegranskat)abstract
- This paper addresses the main progresses and achievements of the H2020 STRATOFLY Project, funded by the European Commission, under the Horizon 2020 framework, specifically looking at the latest results in terms of environmental sustainability. In particular, starting from reporting the main environmental challenges posed by high-speed civil transportation, at local, regional and global levels, this paper describes the way in which the STRATOFLY MR3 vehicle, a Mach 8 waverider fueled with liquid hydrogen, promises to limit the overall environmental impact. In details, firstly, the paper describes some of the main technological improvements adopted to reduce the aircraft emission and then it reports about the status of the numerical and experimental test campaigns on the high-speed engine, showing the results achieved so far. This preliminary emission inventory allows for the evaluation of emission indexes throughout the mission profile, the verification of the compliance with the ICAO prescriptions, the estimation of the impact on air quality and climate and eventually, when necessary, the paper proposes adequate mitigation actions.
|
|
